- January 12, 2021
- Posted by: Bastion team
- Category: Markets
(RTTNews) – Vir Biotechnology, Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) announced Tuesday an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial.
The trial is due to begin in the first quarter of 2021.
VIR-7832 is a neutralizing COVID-19 antibody…
Bastion Balance Seoul, Korea.